Long Focus Capital Management, LLC Cellectis S.A. Transaction History
Long Focus Capital Management, LLC
- $2.69 Billion
- Q3 2025
A detailed history of Long Focus Capital Management, LLC transactions in Cellectis S.A. stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 4,123,262 shares of CLLS stock, worth $16.2 Million. This represents 0.43% of its overall portfolio holdings.
Number of Shares
4,123,262
Previous 4,717,293
12.59%
Holding current value
$16.2 Million
Previous $7.22 Million
60.54%
% of portfolio
0.43%
Previous 0.33%
Shares
9 transactions
Others Institutions Holding CLLS
# of Institutions
33Shares Held
9.71MCall Options Held
52.8KPut Options Held
0-
B Group, Inc. Dallas, TX3.28MShares$12.9 Million6.88% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$5.67 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$893,8870.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il222KShares$874,5180.0% of portfolio
-
Morgan Stanley New York, NY87.7KShares$345,4390.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $179M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...